Prior Authorization Delays Linked to Higher GLP-1 Treatment Discontinuation Risk
Key Takeaways:
- A survey presented at ObesityWeek 2026 found that prior authorization delays of 8 days or longer were associated with more than 10 times the odds of glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment discontinuation compared with patients who did not require prior authorization.
- Patients who reported greater knowledge of whom to contact following an insurance denial had significantly lower odds of treatment discontinuation.
- The findings highlight opportunities for payers and health care providers to improve prior authorization processes, insurance navigation, and communication to support treatment continuity.
Prolonged prior authorization delays and limited knowledge of insurance denial procedures were associated with increased likelihood of GLP-1 RA treatment discontinuation among adults receiving obesity treatment, according to research presented at ObesityWeek 2026.
The findings, presented in poster 626, Prior Authorization Delays and Insurance Denial Knowledge in GLP-1 RA Discontinuation, suggest that administrative barriers and insurance navigation challenges may contribute to treatment interruptions, highlighting opportunities to improve medication access and continuity of care.
Survey Examines Administrative Barriers to Treatment
Researchers at Vanderbilt University Medical Center identified adults who initiated GLP-1 RAs for obesity between January 2018 and December 2023 and experienced a treatment gap exceeding 90 days.
Of 4890 patients invited to participate, 261 completed an 87-item survey examining prior authorization experiences, insurance knowledge, and treatment access barriers, representing a 5.3% response rate.
Most respondents were female (80.5%), non-Hispanic White (72.4%), and covered by employer-sponsored or commercial insurance (71.3%).
The primary outcome was self-reported treatment discontinuation, defined as a medication gap of at least 14 days during the preceding 6 months.
Researchers used adjusted logistic regression models to evaluate associations between discontinuation and prior authorization delays or knowledge of insurance denial procedures.
Longer Authorization Delays Associated With Treatment Interruptions
Among 126 patients included in the prior authorization analysis, waiting 8 days or longer was associated with significantly higher odds of treatment discontinuation compared with not requiring prior authorization (odds ratio [OR], 10.23; 95% CI, 2.69-39.04; P < .001).
Shorter delays of fewer than 8 days were not significantly associated with discontinuation (OR, 2.82; 95% CI, 0.82-9.66; P = .10).
In a separate analysis of 134 patients, each 1-point increase on a 5-point scale measuring knowledge of whom to contact following an insurance denial was associated with 37% lower odds of discontinuation (OR, 0.63; 95% CI, 0.46-0.88; P = .005).
Implications for Managed Care
The findings suggest that reducing authorization delays and improving patient understanding of insurance procedures may help support GLP-1 RA treatment continuity.
Potential strategies include clearer communication about authorization requirements, more accessible denial navigation resources, and improved coordination among payers, prescribers, and patients.
However, the study's low response rate, small analytic samples, and reliance on self-reported information limit generalizability. Its observational design also prevents conclusions about causation.
Conclusion
Prior authorization delays of at least 8 days and limited insurance navigation knowledge were associated with greater GLP-1 RA treatment discontinuation among surveyed patients with obesity.
Further research is needed to determine whether streamlined authorization processes and targeted patient education can reduce avoidable treatment interruptions.
Reference
Zhang X, Feng Y, Piantek G, et al. Prior authorization delays and insurance denial knowledge in GLP-1 RA discontinuation. Poster 626. Session presented at: ObesityWeek; November 14-17, 2026; National Harbor, MD.


